Marijuana For Fibromyalgia

by | Aug 6, 2021 | Health & Relief

Updated on November 26, 2021. Medical content reviewed by Dr. Shatha Atiya.


The lead: pain a short picture of your story, include a critical piece of info that keeps the reader going. Include a hook.


Build your arguments and make your points, throw in quotes, and add my journalistic opinion to add controversy.

Ways I can approach this post:

Best strains approach (Leafly got a lot of engagement) Include a tiny section for this

CBD oil approach (Keywords have a lot of volumes) Include a tiny section

Include the benefits of marijuana

Benefits of MMJ for fibromyalgia: pain relief, alleviate sleep problems, muscle stiffness, mood problems, anxiety, headaches, nausea, muscle spasms, quality of life

Fibromyalgia is a chronic pain syndrome, characterized by chronic musculoskeletal pain, fatigue, and mood disturbances. There are nearly no data on the effect of medical cannabis (MC) treatment on patients with fibromyalgia.

After commencing MC treatment, all the patients reported a significant improvement in every parameter on the questionnaire, and 13 patients (50%) stopped taking any other medications for fibromyalgia. Eight patients (30%) experienced very mild adverse effects.[]

After 2 hours of cannabis use, VAS scores showed a statistically significant (p<0.001) reduction of pain and stiffness, enhancement of relaxation, and an increase in somnolence and feeling of well being. []

Various authors ( Russo, 2008; Smith & Wagner, 2014 )
have suggested that some diseases are associated with
the suboptimal functioning of the endocannabinoid system. Known collectively as clinical endocannabinoid
defi ciency syndromes (CEDS), these dysfunctions have
been proposed as being responsible for migraine, fi bromyalgia, irritable bowel syndrome, and related conditions. It has been suggested that interventions enhancing
the endocannabinoid system—upregulating cannabinoid receptors, increasing ligand synthesis, and inhibiting ligand degradation—could be useful for CEDS
( McPartland et al., 2014 ).

There is a limited number of clinical studies assessing the effi cacy of cannabinoids (natural or synthetic) in
the treatment of fi bromyalgia symptoms. Most evidence
comes from surveys and observational studies with a few
RCTs ( Lynch & Campbell, 2011; Lynch & Ware, 2015 ).

A recent survey from the National Pain Foundation
showed that medical marijuana may top currently available medicines for treating fi bromyalgia ( Anson, 2014 ).
The survey, which was conducted online, asked more
than 1300 patients with fi bromyalgia to rate the effectiveness of the treatments that they had used. Medical marijuana was compared with the three drugs approved by
the FDA for fi bromyalgia: milnacipran (Savella), pregabalin (Lyrica), and duloxetine (Cymbalta) ( Table e16.4 ).
Only 8% of the patients that tried duloxetine, and 10%
that tried pregabalin or milnacipran, found the drugs to
be “very effective” for managing symptoms of the disorder. Over 60% of the patients reported that each of three
drugs “does not help at all.” On the other hand, 62% of
the patients who tried medical marijuana found it to be
“very effective.” Another 33% said it “helps a little,” and
5% felt that using cannabis for fi bromyalgia “does not
help at all.”


The study focused on treating refractory patients – meaning people who are stably taking medications, but haven’t found relief. Just under half of their patients were taking two other drugs, while nearly a third took at least three. These drugs were severe central sedatives, including opioids, anti-convulsants, nerve blockers, and anti-depressants.

Given the intensity of the drugs people were already taking, it was astounding to find that half of patients (47%) got enough relief from cannabis to reduce or cease their painkiller usage.

There was no set dosing regime — medical research thus far has not settled on a single dose, and it is unrealistic to suspect that one ideal dose exists, considering the variety of conditions that cannabis can help treat.

The researchers instead recommended that participants try 10-30 drops in each morning and evening dose. Titrating slowly based on their own comfort, they could take up to 120 drops per day. This might mean starting with as little as 4 mg THC and 2 mg CBD — broken into two doses. The higher doses would have been close to 27 mg THC and 8 mg CBD, with most of the THC taken at night.

Dr. Ethan Russo hypothesizes that fibromyalgia, along with migraine, may be an expression of a clinical endocannabinoid deficiency syndrome. This theory proposes that certain diseases manifest when the endocannabinoid system is too weak to properly regulate the many physiological systems under its control. If endocannabinoid deficits cause certain diseases, then taking plant cannabinoids like CBD and THC will address the root of the disease, rather than merely mitigating some symptoms. []

Cannabis may be a better analgesic in men compared to women…These results indicate that in cannabis smokers, men exhibit greater cannabis-induced analgesia relative to women. These sex-dependent differences are independent of cannabis-elicited subjective effects associated with abuse-liability, which were consistent between men and women. As such, sex-dependent differences in cannabis’s analgesic effects are an important consideration that warrants further investigation when considering the potential therapeutic effects of cannabinoids for pain relief. *NOT RELATED TO FOBROMYALGIA*[]


End with my journalistic assessment.